日本多中心Viabahn肝素涂层支架移植治疗长段复杂股浅动脉病变的长期结果
这项前瞻性多中心研究在15家日本医院评估肝素涂层支架移植治疗长段复杂股浅动脉病变的长期安全性和有效性。103例患者(平均年龄74.2岁,82.5%男性)纳入,平均病变长度21.8 cm,84.5%为TASC C或D级。24个月主要辅助通畅率85.7%,免于靶病变血运重建率87.2%,60个月为79.1%;5年内无肢体威胁性事件、急性肢体缺血或支架断裂。
要点
- 长段复杂股浅动脉病变置入肝素涂层支架移植后24个月主要辅助通畅率达85.7%。
- 5年随访免于靶病变血运重建率为79.1%,无截肢、急性肢体缺血或支架断裂。
- ABI从基线0.64±0.12显著改善至24个月0.94±0.19(P<.0001)。
核心结论
- 肝素涂层支架移植治疗跛行患者长段复杂股浅动脉病变在长期随访中安全有效,5年免于靶病变血运重建率79.1%,无截肢、急性肢体缺血或支架断裂。
研究设计与样本
- 前瞻性多中心研究,在日本15家医院纳入103例有症状外周动脉疾病患者,平均年龄74.2±7.0岁,82.5%为男性。
- 纳入标准为Rutherford 2至5级症状(5级无活动性感染)、踝肱指数≤0.9、股浅动脉病变长度≥10 cm且狭窄≥50%。
- 主要疗效和安全性结局分别为24个月主要辅助通畅率和不良事件,次要结局包括一期通畅率、二期通畅率、免于靶病变血运重建率和血管生活质量问卷评分。
主要发现
- 平均病变长度21.8±5.8 cm,87处病变(84.5%)为TASC C或D级,65.7%为慢性完全闭塞。
- 24个月Kaplan-Meier估计的主要辅助通畅率、一期通畅率和二期通畅率分别为85.7%(95%CI 76.3%-91.5%)、78.8%(95%CI 68.8%-85.9%)和92.0%(95%CI 82.4%-96.5%)。
- 24个月和60个月免于靶病变血运重建率分别为87.2%(95%CI 78.9%-92.3%)和79.1%(95%CI 67.9%-86.8%)。
- 平均踝肱指数从基线0.64±0.12改善至24个月0.94±0.19(P<.0001)。
- 5年随访期间无器械或手术相关的危及生命或肢体的严重事件,无急性肢体缺血,年度随访X线未发现支架断裂;1例患者需转为开放旁路手术。
关键数值与推荐
- 24个月主要辅助通畅率85.7%(95%CI 76.3%-91.5%),一期通畅率78.8%(95%CI 68.8%-85.9%),二期通畅率92.0%(95%CI 82.4%-96.5%)。
- 24个月和60个月免于靶病变血运重建率分别为87.2%(95%CI 78.9%-92.3%)和79.1%(95%CI 67.9%-86.8%)。
- 基线平均踝肱指数0.64±0.12,24个月0.94±0.19(P<.0001)。
- 血管生活质量问卷和步行障碍问卷评分在1至24个月较基线显著提高(两者P<.0001)。
临床怎么用
- 对于跛行患者的长段复杂股浅动脉病变,肝素涂层支架移植可作为安全有效的腔内治疗选择。
- 长期随访中免于靶病变血运重建率较高,且无支架断裂或急性肢体缺血,支持其用于复杂病变。
- 术后需定期影像学随访以监测支架通畅性和断裂情况。
局限性
- 103例患者中仅92例可评估至24个月,61例可评估至60个月,长期随访样本量减少。
- 本研究为单臂前瞻性研究,无对照组,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We assessed the long-term safety and efficacy of endovascular stent grafting to treat long, complex lesions in the superficial femoral artery (SFA). METHODS: The present prospective, multicenter study at 15 Japanese hospitals assessed heparin-bonded stent grafts used to treat long SFA lesions in patients with symptomatic peripheral arterial disease. The inclusion criteria were Rutherford category 2 to 5 symptoms (grade 5 without active infection), an ankle brachial index of ≤0.9, and SFA lesions ≥10 cm long with ≥50% stenosis. The key efficacy and safety outcomes were primary-assisted patency and adverse events through 24 months, respectively. The secondary outcomes included primary patency, secondary patency, freedom from target lesion revascularization (fTLR), and Vascular Quality of Life questionnaire score. RESULTS: Of the 103 patients (mean age, 74.2 ± 7.0 years; 82.5% male), 100 (97.1%) had intermittent claudication. The average lesion length was 21.8 ± 5.8 cm; 87 lesions (84.5%) were TASC (Trans-Atlantic Inter-Society Consensus Document on Management of Peripheral Arterial Disease) C or D (65.7% chronic total occlusions). Of the 103 patients, 92 and 61 were evaluable through 24 and 60 months, respectively. At 24 months, the Kaplan-Meier-estimated primary-assisted patency, primary patency, and secondary patency rate was 85.7% (95% confidence interval [CI], 76.3%-91.5%), 78.8% (95% CI, 68.8%-85.9%), and 92.0% (95% CI, 82.4%-96.5%), respectively. The mean ankle brachial index was 0.64 ± 0.12 at baseline and 0.94 ± 0.19 at 24 months (P < .0001). At 24 and 60 months, the fTLR was 87.2% (95% CI, 78.9%-92.3%) and 79.1% (95% CI, 67.9%-86.8%), respectively. No device- or procedure-related life- or limb-threatening critical events or acute limb ischemia cases were observed through 5 years. No stent fractures were detected on the annually scheduled follow-up radiographs. The vascular quality of life questionnaire and walking impairment questionnaire scores were significantly increased at 1 through 24 months compared with the baseline scores (P < .0001 for both). One patient had required conversion to open bypass during the 5-year follow-up period. CONCLUSIONS: Stent grafting of long and complex SFA lesions in patients with claudication is safe and effective through long-term follow-up, with 79.1% fTLR and no leg amputation, acute limb ischemia, or stent fractures through 5 years.
引用
- Ohki T, Kichikawa K, Yokoi H, et al. Long-term results of the Japanese multicenter Viabahn trial of heparin bonded endovascular stent grafts for long and complex lesions in the superficial femoral artery. J Vasc Surg. 2021. PMID: 34182032. doi:10.1016/j.jvs.2021.05.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。